Pentadeca Arginate (PDA) vs Sermorelin

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

Pentadeca Arginate (PDA)Sermorelin
CategoryPeptidesPeptides
Standard DoseResearch indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection.Research indicates 200-300 mcg administered once daily at bedtime via subcutaneous injection.
TimingAdminister on an empty stomach. Inject near site of injury for localized effect.Bedtime administration (aligns with natural nocturnal GH release). On empty stomach.
Cycle Duration4-12 weeks depending on therapeutic target.12-24 week cycles. Some protocols use continuous treatment.
Evidence Levelanimal_plus_anecdotalstrong_human

Mechanism

Pentadeca Arginate is a synthetic 15-amino acid peptide utilizing an arginate salt formulation of the BPC-157 sequence, designed to enhance nitric oxide production and promote angiogenesis. It stimulates collagen synthesis, enhances tissue repair through increased tensile strength, reduces inflammation via modulation of inflammatory cytokines, and accelerates cellular proliferation in tendon fibroblasts. The arginate salt form provides superior stability and bioavailability compared to traditional acetate formulations.

Standard Dosing

Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection.

Timing

Administer on an empty stomach. Inject near site of injury for localized effect.

Cycle Duration

4-12 weeks depending on therapeutic target.

Side Effects

  • Mild nausea (rare)
  • Injection site irritation
  • Headache (uncommon)

Contraindications

  • Active cancer
  • Pregnancy and breastfeeding
  • Children under 18

Best Stacking Partners

TB-500GHK-CuCJC-1295/Ipamorelin
B

Sermorelin

Peptides

Mechanism

Sermorelin is a synthetic 29-amino acid peptide representing the biologically active fragment of GHRH (amino acids 1-29) with full functional activity. It activates GHRH receptors on pituitary somatotrophs, stimulating cAMP production via Gs protein/adenylate cyclase and MAP kinase pathways. Due to the interactive effects of sermorelin and endogenous somatostatin, GH release is episodic rather than continuous. Sermorelin also stimulates pituitary gene transcription of GH mRNA, increasing and preserving pituitary GH reserve.

Standard Dosing

Research indicates 200-300 mcg administered once daily at bedtime via subcutaneous injection.

Timing

Bedtime administration (aligns with natural nocturnal GH release). On empty stomach.

Cycle Duration

12-24 week cycles. Some protocols use continuous treatment.

Side Effects

  • Injection site reactions
  • Facial flushing
  • Headache
  • Dizziness
  • Transient taste changes

Contraindications

  • Active cancer
  • Pregnancy and breastfeeding
  • Intracranial hypertension

Best Stacking Partners

IpamorelinGHRP-2GHRP-6

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →